AptarGroup, Inc. (ATR)
| Market Cap | 8.29B -2.4% |
| Revenue (ttm) | 3.93B +8.9% |
| Net Income | 362.52M -7.4% |
| EPS | 5.55 -4.1% |
| Shares Out | 63.58M |
| PE Ratio | 23.49 |
| Forward PE | 22.28 |
| Dividend | $1.92 (1.47%) |
| Ex-Dividend Date | Jul 30, 2026 |
| Volume | 405,594 |
| Open | 128.63 |
| Previous Close | 127.17 |
| Day's Range | 128.36 - 130.72 |
| 52-Week Range | 103.23 - 146.91 |
| Beta | 0.34 |
| Analysts | Buy |
| Price Target | 162.25 (+24.45%) |
| Earnings Date | Oct 29, 2026 |
About ATR
AptarGroup, Inc. designs and manufactures drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, fragrance, facial skincare, color cosmetics, personal care, home care, and food and beverage markets. The company operates through three segments: Pharma, Beauty, and Closures. It provides dispensing pumps used to dispense sprays, liquids, or lotions from non-pressurized containers; fine-mist pumps for pharmaceutical and fragrance applications; and lotion pumps for viscous formulations,... [Read more]
Financial Performance
In 2025, AptarGroup's revenue was $3.78 billion, an increase of 5.42% compared to the previous year's $3.58 billion. Earnings were $392.79 million, an increase of 4.87%.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for ATR stock is "Buy." The 12-month stock price target is $162.25, which is an increase of 24.45% from the latest price.
News
Aptar Pharma enters collaboration with Stevanato Group
Aptar Pharma, part of AptarGroup (ATR) announced a collaboration with Stevanato Group (STVN) to provide system-level data supporting earlier evaluation of pre-filled syringe configurations for biotech...
AptarGroup initiated with a Neutral at UBS
UBS analyst Anojja Shah initiated coverage of AptarGroup (ATR) with a Neutral rating and $135 price target The company has a “robust moat” in its pharma segment, which represents 70%…
AptarGroup initiated with a Buy at Deutsche Bank
Deutsche Bank initiated coverage of AptarGroup (ATR) with a Buy rating and $150 price target The firm views the shares as “mispriced” given the company’s leading positions in nasal, ophthalmic…
AptarGroup price target lowered to $154 from $172 at BofA
BofA lowered the firm’s price target on AptarGroup (ATR) to $154 from $172 and keeps a Buy rating on the shares as the firm adjusted targets among its packaging and…
AptarGroup Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Leadership is focused on delivering 2026 commitments and long-term growth, with the Pharma segment as a key driver. Innovation, pipeline expansion, and a diversified revenue model support robust margins and growth, while a strong balance sheet enables continued investment and shareholder returns.
AptarGroup, Massachusetts General Hospital team on nose-to-brain drug delivery
AptarGroup (ATR) announced that it has signed an agreement for a research collaboration led by Alice Stanton from Massachusetts General Hospital, or MGH, to advance the science of nose-to-brain drug…
AptarGroup Transcript: Wells Fargo 21st Annual Healthcare Conference
Leadership is prioritizing customer centricity, innovation, and execution, with a focus on improving underperforming segments and leveraging early-stage partnerships in pharma. Beauty lags in North America, while pharma and injectables show strong growth. Major investments are complete, and IP protection remains a key focus.
AptarGroup price target lowered to $172 from $173 at BofA
BofA lowered the firm’s price target on AptarGroup (ATR) to $172 from $173 and keeps a Buy rating on the shares. The firm lowered its EPS forecasts for Q3, 2026…
AptarGroup Earnings Call Transcript: Q2 2026
Second quarter saw record sales and adjusted EPS above guidance, led by strong Pharma demand in injectables and consumer healthcare, while Beauty and Closures improved sequentially. Emergency medicine headwinds are expected to ease, supporting margin recovery and long-term growth targets.
AptarGroup Earnings release: Q2 2026
AptarGroup released its Q2 2026 earnings on July 31, 2026, summarizing the period's financial results.
AptarGroup Slides: Q2 2026
AptarGroup has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 31, 2026.
AptarGroup Quarterly report: Q2 2026
AptarGroup has published its Q2 2026 quarterly earnings report on July 31, 2026.
AptarGroup reports Q2 EPS $1.36, consensus $1.35
Reports Q2 revenue $1.03B, consensus $1.01B. “We were pleased to deliver revenue growth across all three segments during the quarter. Aptar Pharma continued to lead the way, driven by double-digit…
AptarGroup sees Q3 EPS $1.45-$1.53, consensus $1.46
Regarding Aptar’s outlook, Tanda stated, “In alignment with Gael Touya, who will assume the role of CEO on September 1, we enter the third quarter with confidence. We expect solid…
Aptar Named One of the World's Most Sustainable Companies by TIME for Third Consecutive Year
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that it has be...
Aptar Beauty Launches Next-Generation Auto-Loading Dropper Technology for Easier, More Accurate Skincare Dosing
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, announces the first commercial ...
AptarGroup Slides: Corporate presentation
AptarGroup has posted slides in relation to its latest quarterly earnings report, which was published on July 20, 2026.
Aptar Declares Quarterly Dividend
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that the Board...
AptarGroup price target raised to $160 from $150 at Raymond James
Raymond James raised the firm’s price target on AptarGroup (ATR) to $160 from $150 and keeps an Outperform rating on the shares. Near-term Narcan destocking remains a headwind, but improving…
AptarGroup upgraded to Buy from Neutral at BofA
BofA upgraded AptarGroup (ATR) to Buy from Neutral with a price target of $173, up from $148.
Aptar Releases 2025 Corporate Sustainability Report
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Releases 2025 Corporate Sustainability Report.
AptarGroup Transcript: 16th Annual Wells Fargo Industrials & Materials Conference
Global operations delivered $3.8B in 2025 revenue, led by pharma, with strong innovation and a robust patent portfolio. Pharma remains the growth engine, supported by a diversified pipeline and new drug delivery technologies. Beauty and closures segments are recovering, with margin improvements expected as operational challenges are resolved.
AptarGroup Slides: 16th Annual Wells Fargo Industrials & Materials Conference
AptarGroup has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
AptarGroup Transcript: Jefferies Global Healthcare Conference 2026
Global operations generated $3.8 billion in 2025, with Pharma as the main growth engine and a diverse, innovation-driven pipeline supporting a 7%-11% long-term growth target. Recent investments focus on automation, while injectables and high-value products show strong momentum.